Ignite Creation Date:
2024-10-26 @ 3:35 PM
Last Modification Date:
2024-10-26 @ 3:35 PM
Study NCT ID:
NCT06508320
Status:
ACTIVE_NOT_RECRUITING
Last Update Posted:
None
First Post:
2024-07-12
Brief Title:
A Clinical Study to Investigate the Safety and Immunogenicity in Relation to Product Attributes of mRNA-1083 Severe Acute Respiratory Syndrome Coronavirus 2 SARS-CoV-2 and Influenza Vaccine
Sponsor:
None
Organization:
None
Study Overview
Official Title:
A Phase 2 Randomized Observer-blind Study to Evaluate the Safety Reactogenicity and Immunogenicity in Relation to the Product Attributes of mRNA-1083 SARS-CoV-2 and Influenza Vaccine in Adults 50 to 65 Years of Age
Status:
ACTIVE_NOT_RECRUITING
Status Verified Date:
2024-08
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
No
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
The purpose of this study is to evaluate the safety reactogenicity and immunogenicity in relation to the product attributes of mRNA-1083 vaccine when administered as a single intramuscular IM injection in adults 50 to 65 years of age
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None